1
|
Ma J, Chen T, Zhang J, Cao W, Gao G, Yu X, Wang H. Enhanced outcomes in residual or recurrent craniopharyngioma: evaluating combined gamma knife and phosphorus-32 brachytherapy. Clin Transl Oncol 2024:10.1007/s12094-024-03435-2. [PMID: 38488982 DOI: 10.1007/s12094-024-03435-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2024] [Accepted: 03/02/2024] [Indexed: 03/17/2024]
Abstract
BACKGROUND Managing residual and recurrent craniopharyngioma effectively is crucial for improving patient outcomes. This study evaluates the combined use of gamma knife and phosphorus-32 brachytherapy, offering insights into alternative, less invasive treatment strategies. METHODS We conducted a retrospective analysis of 97 patients treated from 2010 to 2016 for residual and recurrent craniopharyngioma using gamma knife and phosphorus-32 brachytherapy. We classified these patients into three groups: superficial solid (Group A), simple cystic (Group B), and mixed cystic-solid (Group C). We assessed the treatment's effectiveness by the tumor control rates and evaluated safety by monitoring vision, endocrine function improvements, and complication rates. RESULTS The treatment achieved complete and adequate control rates of 49.5% and 87.6%, respectively. We observed improvements in vision or visual fields in 55.1% of the patients. The morbidity rate was 15.5%. The study found no significant differences in tumor control rates among the various lesion types. CONCLUSION The combination of gamma knife and phosphorus-32 brachytherapy presents a viable, minimally invasive alternative for treating residual and recurrent craniopharyngioma. It offers high tumor control and functional improvement rates, suggesting its potential as a preferred strategy in some instances.
Collapse
Affiliation(s)
- Jie Ma
- PLA Medical School, Beijing, 100853, People's Republic of China
- Department of Neurosurgery, Chinese PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing, 100853, People's Republic of China
| | - Tao Chen
- State Key Laboratory of Industrial Control Technology, Zhejiang University, Hangzhou, 310027, People's Republic of China
| | - Jianning Zhang
- Department of Neurosurgery, Chinese PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing, 100853, People's Republic of China
| | - Weidong Cao
- Department of Neurosurgery, Chinese PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing, 100853, People's Republic of China
| | - Gan Gao
- PLA Medical School, Beijing, 100853, People's Republic of China
- Department of Neurosurgery, Chinese PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing, 100853, People's Republic of China
| | - Xinguang Yu
- Department of Neurosurgery, Chinese PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing, 100853, People's Republic of China.
| | - Hongwei Wang
- Department of Neurosurgery, Chinese PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing, 100853, People's Republic of China.
| |
Collapse
|
2
|
Peiró-Valgañón V, Guardiola-Arévalo A, López Fernández A, Llorente Herrero E, Martín Fernández-Gallardo MT. A multidisciplinary challenge: Therapy with phosphorus-32 for locally advanced pancreatic cancer. Rev Esp Med Nucl Imagen Mol 2023; 42:403-409. [PMID: 37788763 DOI: 10.1016/j.remnie.2023.09.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2023] [Accepted: 09/06/2023] [Indexed: 10/05/2023]
Abstract
Pancreatic cancer is a disease with a poor prognosis, and overall survival has improved the least in the last 40 years of all cancers. Locally advanced pancreatic adenocarcinoma, without distant metastasis but with limiting vascular involvement, constitutes almost one third of these patients. This group is the focus of most research efforts to introduce treatments to increase surgical salvage rates and/or survival, with two main objectives: local control and prevention of systemic progression. Intratumoural treatment with phosphorus-32 microparticles, guided by echoendoscopy and combined with standard chemotherapy may have significant and clinically relevant benefits in these patients, and therefore a valuable treatment option in a disease where there is an urgent need to develop new therapies to help improve outcomes.
Collapse
Affiliation(s)
- V Peiró-Valgañón
- Departamento de Medicina Nuclear, Diagnóstico por la Imagen, Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain.
| | - A Guardiola-Arévalo
- Departamento de Gastroenterología, Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain
| | - A López Fernández
- Servicio de Radiofísica y Protección Radiológica, Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain
| | - E Llorente Herrero
- Departamento de Medicina Nuclear, Diagnóstico por la Imagen, Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain
| | - M T Martín Fernández-Gallardo
- Departamento de Radiología Abdominal, Diagnóstico por la Imagen, Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain
| |
Collapse
|
3
|
Olyaei E, Mohammadzadeh M, Azimi P. Comparative study of Lutetium-177 and Phosphorus-32 in radioactive bone cement for the treatment of vertebral body metastasis. J Cancer Res Clin Oncol 2023; 149:7479-7491. [PMID: 36959343 DOI: 10.1007/s00432-023-04695-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2023] [Accepted: 03/14/2023] [Indexed: 03/25/2023]
Abstract
BACKGROUND Vertebroplasty is a minimally invasive outpatient procedure to stabilize compression fractures in the spine. This procedure involves injecting bone cement into the vertebrae that have been cracked or broken, typically due to osteoporosis. The cement hardens inside the bones, providing stability to the fractures and supporting the spine. Additionally, radioactive bone cement and brachytherapy sources have been utilized to suppress tumor growth in the vertebral body. OBJECTIVE We present a novel brachytherapy technique for treating vertebral body metastases using a liquid form of radioactive sources, Phosphorus-32 and Lutetium-177, separately mixed with bone cement and injected into vertebral body bone prostheses. We also investigated the dose distribution of the radioactive bone cement by theoretically calculating it using GEANT4 Monte Carlo and measuring it using TLD dosimeters for Phosphorus-32 and Lutetium-177 loaded in vertebral bodies. MATERIAL AND METHODS CT-scanned images of each vertebral body (L2 and L3) were imported into GEANT4 for simulation purposes. Two simulations were performed to evaluate the possibility of using PLA prostheses in ex vivo measurements, using bone and PLA material as a bone substitute for brachytherapy of Lutetium-177 and Phosphorus-32. The simulations calculated the dose distribution, dose rates, and deposited dose to the spinal cord and aorta. Next, 3D-printed bone prostheses were drilled and separately filled with bone cement, including PMMA-P32 and PMMA-Lu177, in liquid form using the Vertebroplasty technique. The dose to regions of interest was measured using Thermoluminescence dosimeters. CONCLUSIONS When comparing the simulated and measured results of dose rates, it was observed that P32 delivers higher doses to normal organs such as the spinal cord and aorta. At the same time, Lu177 has better sparing in these regions of interest. Therefore, while P32 and Lu177 are suitable for radioactive bone cement treatment, Lu177 delivers relatively lower doses to vital organs such as the spinal cord and aorta. Additionally, Lu177 has characteristics such as a shorter range and lower energies of beta particles in tissue and the presence of gamma rays that make it a better choice for the same treatments. It also provides the possibility of SPECT imaging.
Collapse
Affiliation(s)
- Elnaz Olyaei
- Department of Medical Radiation Engineering, Shahid Beheshti University, Tehran, Iran.
| | | | - Parisa Azimi
- Neuroscience Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
| |
Collapse
|
4
|
Italiano A, Pistone D, Amato E, Baldari S, Auditore L. Internal Bremsstrahlung, the missing process in beta decay Monte Carlo simulation: The relevance in 32P Dose-Point-Kernel estimation. Phys Med 2023; 110:102585. [PMID: 37119675 DOI: 10.1016/j.ejmp.2023.102585] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/02/2022] [Revised: 03/03/2023] [Accepted: 04/07/2023] [Indexed: 05/01/2023] Open
Abstract
PURPOSE In nuclear medicine, Dose Point Kernels (DPKs), representing the energy deposited all around a point isotropic source, are extensively used for dosimetry and are usually obtained by Monte Carlo (MC) simulations. For beta-decaying nuclides, DPK is usually estimated neglecting Internal Bremsstrahlung (IB) emission, a process always accompanying the beta decay and consisting in the emission of photons having a continuous spectral distribution. This work aims to study the significance of IB emission for DPK estimation in the case of 32P and provide DPK values corrected for the IB photon contribution. METHODS DPK, in terms of the scaled absorbed dose fraction, F(R/X90), was first estimated by GAMOS MC simulation using the standard beta decay spectrum of 32P, Fβ(R/X90). Subsequently, an additional source term accounting for IB photons and their spectral distribution was defined and used for a further MC simulation, thus evaluating the contribution of IB emission to DPK values, Fβ+IB(R/X90). The relative percent difference, δ, between the DPKs obtained by the two approaches, Fβ+IB vs. Fβ, was studied as a function of the radial distance, R. RESULTS As far as the energy deposition is mainly due to the beta particles, IB photons does not significantly contribute to DPK; conversely, for larger R, Fβ+IB values are higher by 30-40% than Fβ. CONCLUSIONS The inclusion of IB emission in the MC simulations for DPK estimations is recommended, as well as the use of the DPK values corrected for IB photons, here provided.
Collapse
Affiliation(s)
- Antonio Italiano
- INFN, National Institute for Nuclear Physics, Section of Catania, Italy; MIFT Department, University of Messina, Italy
| | - Daniele Pistone
- INFN, National Institute for Nuclear Physics, Section of Catania, Italy; Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Italy.
| | - Ernesto Amato
- INFN, National Institute for Nuclear Physics, Section of Catania, Italy; Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Italy; Health Physics Unit, University Hospital 'Gaetano Martino', Messina, Italy
| | - Sergio Baldari
- Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Italy; Nuclear Medicine Unit, University Hospital 'Gaetano Martino', Messina, Italy
| | - Lucrezia Auditore
- INFN, National Institute for Nuclear Physics, Section of Catania, Italy; Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Italy
| |
Collapse
|
5
|
Silva JT, Daruich de Souza C, Angelocci LV, Arcos Rosero WA, Nogueira BR, Correia RW, Zeituni CA, Chuery Martins Rostelato ME. New model for an epoxy-based brachytherapy source to be used in spinal cancer treatment. Appl Radiat Isot 2021; 178:109952. [PMID: 34601270 DOI: 10.1016/j.apradiso.2021.109952] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2021] [Revised: 08/25/2021] [Accepted: 09/13/2021] [Indexed: 10/20/2022]
Abstract
The present work described the cold fabrication of a P-32 radioactive source to be used in CNS cancer using epoxy resin. The epoxy plaque fabricated with Teflon mold presented better agreement. MCNP simulation evaluated the radiation dose. Special attention was given to factors that can impact dose distribution. Average dose was 16.44 ± 2.89% cGy/s. Differences of less than 0.01 cm in thickness within the plaque lead to differences of up to 12% in the dose rate.
Collapse
Affiliation(s)
- José T Silva
- Laboratório de Produção de Fontes para Radioterapia, Instituto de Pesquisas Energéticas e Nucleares (IPEN / CNEN - SP), Universidade de São Paulo, Av. Professor Lineu Prestes 2242, 05508-000, São Paulo, SP, Brazil.
| | - Carla Daruich de Souza
- Laboratório de Produção de Fontes para Radioterapia, Instituto de Pesquisas Energéticas e Nucleares (IPEN / CNEN - SP), Universidade de São Paulo, Av. Professor Lineu Prestes 2242, 05508-000, São Paulo, SP, Brazil.
| | - Lucas Verdi Angelocci
- Laboratório de Produção de Fontes para Radioterapia, Instituto de Pesquisas Energéticas e Nucleares (IPEN / CNEN - SP), Universidade de São Paulo, Av. Professor Lineu Prestes 2242, 05508-000, São Paulo, SP, Brazil.
| | - Wilmmer Alexander Arcos Rosero
- Laboratório de Produção de Fontes para Radioterapia, Instituto de Pesquisas Energéticas e Nucleares (IPEN / CNEN - SP), Universidade de São Paulo, Av. Professor Lineu Prestes 2242, 05508-000, São Paulo, SP, Brazil.
| | - Beatriz Ribeiro Nogueira
- Laboratório de Produção de Fontes para Radioterapia, Instituto de Pesquisas Energéticas e Nucleares (IPEN / CNEN - SP), Universidade de São Paulo, Av. Professor Lineu Prestes 2242, 05508-000, São Paulo, SP, Brazil.
| | - Ruanyto Willy Correia
- Laboratório de Produção de Fontes para Radioterapia, Instituto de Pesquisas Energéticas e Nucleares (IPEN / CNEN - SP), Universidade de São Paulo, Av. Professor Lineu Prestes 2242, 05508-000, São Paulo, SP, Brazil.
| | - Carlos Alberto Zeituni
- Laboratório de Produção de Fontes para Radioterapia, Instituto de Pesquisas Energéticas e Nucleares (IPEN / CNEN - SP), Universidade de São Paulo, Av. Professor Lineu Prestes 2242, 05508-000, São Paulo, SP, Brazil.
| | - Maria Elisa Chuery Martins Rostelato
- Laboratório de Produção de Fontes para Radioterapia, Instituto de Pesquisas Energéticas e Nucleares (IPEN / CNEN - SP), Universidade de São Paulo, Av. Professor Lineu Prestes 2242, 05508-000, São Paulo, SP, Brazil.
| |
Collapse
|
6
|
Babaei M, Ghahramani-Asl R, Sadoughi HR, Sardari D, Shahzadi S. Evaluation of Bremsstrahlung radiation dose in stereotactically radiocolloid therapy of cystic craniopharyngioma tumors with 32P radio-colloid. Australas Phys Eng Sci Med 2018; 41:697-711. [PMID: 29987510 DOI: 10.1007/s13246-018-0665-4] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/29/2017] [Accepted: 07/05/2018] [Indexed: 11/27/2022]
Abstract
Over 90% of craniopharyngeal brain tumors are cystic, which enables the injection of beta emitters such as phosphorus-32 (32P) radio-colloid into cysts for their treatment. The aim of this study was to evaluate the clinical and theoretical modelling of Bremsstrahlung radiation dose resulting from stereotactic radio-colloid therapy of cystic craniopharyngioma tumors with 32P. 32P radio-colloid with appropriate activity concentration was injected to a head phantom, and then the Bremsstrahlung radiation spectrum and planar images were obtained using a gamma camera. Both phantom and gamma camera were simulated using MCNPX code, and the results were compared with practical results. Bremsstrahlung radiation spectrum was measured using a handheld gamma spectrometer for two patients treated with stereotactic radio-colloid therapy with 32P in different positions and compared to Monte Carlo simulation. Results of counting and determining sensitivity coefficients in the air and the attenuating environment were obtained. Also, comparing the counting sensitivity from practical and simulation methods indicated the agreement of the data between the two methods. Comparison of the spectra from different positions around patient's head indicated the ability to use this detector to quantify the activity in the operating room. Selection of the spectrum is important in Bremsstrahlung radiation imaging. We can take advantage of spectrometry measurement using gamma camera, handheld gamma spectrometer for patient, and theoretical modeling with Monte Carlo code to evaluate radiopharmaceutical distribution, leakage, as well as estimate activity and predict therapeutic effects in other adjacent structures and ultimately optimize radio-colloid therapy in cystic craniopharyngeal patients.
Collapse
|
7
|
Handkiewicz-Junak D, Poeppel TD, Bodei L, Aktolun C, Ezziddin S, Giammarile F, Delgado-Bolton RC, Gabriel M. EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides. Eur J Nucl Med Mol Imaging 2018; 45:846-859. [PMID: 29453701 PMCID: PMC5978928 DOI: 10.1007/s00259-018-3947-x] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2018] [Accepted: 01/11/2018] [Indexed: 11/16/2022]
Abstract
The skeleton is the most common metastatic site in patients with advanced cancer. Pain is a major healthcare problem in patients with bone metastases. Bone-seeking radionuclides that selectively accumulate in the bone are used to treat cancer-induced bone pain and to prolong survival in selected groups of cancer patients. The goals of these guidelines are to assist nuclear medicine practitioners in: (a) evaluating patients who might be candidates for radionuclide treatment of bone metastases using beta-emitting radionuclides such as strontium-89 (89Sr), samarium-153 (153Sm) lexidronam (153Sm-EDTMP), and phosphorus-32 (32P) sodium phosphate; (b) performing the treatments; and
Collapse
Affiliation(s)
- Daria Handkiewicz-Junak
- Nuclear Medicine and Endocrine Oncology Department, Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland.
| | | | - Lisa Bodei
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, USA
| | | | - Samer Ezziddin
- Nuclear Medicine, University Hospital USK, Saarland University, Hamburg, Germany
| | - Francesco Giammarile
- Nuclear Medicine and Diagnostic Imaging Section, International Atomic Energy Agency (IAEA), Vienna, Austria
| | - Roberto C Delgado-Bolton
- Department of Diagnostic Imaging (Radiology) and Nuclear Medicine, University Hospital San Pedro and Centre for Biomedical Research of La Rioja (CIBIR), Logroño, La Rioja, Spain.
| | - Michael Gabriel
- Institute of Nuclear Medicine and Endocrinology, Kepler University Hospital, Linz, Austria
- University Clinic of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria
| |
Collapse
|
8
|
Hao HT, Wang Y, Wang X, Luan S, Cui J, Chen Y, Cui YL. Treatment of Graves' ophthalmopathy with an in-house Phosphorus-32 source: Initial clinical observations. Exp Ther Med 2017; 14:2795-2800. [PMID: 28966670 PMCID: PMC5613199 DOI: 10.3892/etm.2017.4911] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2016] [Accepted: 03/17/2017] [Indexed: 12/04/2022] Open
Abstract
The objective of the present study was to observe the therapeutic effect of radiation delivered via a 32P source on Graves' ophthalmopathy. A32P solution was injected into a 10-ml vacuum flask held inside a lead container. A window was cut in the lead, generating a treatment beam. Radiation was given to four areas: The upper and lower orbit (covering ~1/3 of the eyelid) and the inner and outer canthus. Each site received 10 daily doses of 20 cGy. Proptosis was measured by an exophthalmometer and the palpebral aperture was determined with a ruler. Measurements were taken before and after the treatment. After 5 days of treatment, the patient displayed a significant improvement, and by 10 days, the average reduction of proptosis in Graves' ophthalmopathy was 3.36±1.73 mm for the left and 3.05±2.04 mm for the right eyes. The treatment was effective in all patients, who uniformly reported rapid pain relief. Conjunctival congestion and eyelid edema also improved significantly. However, only 50% of patients showed improved diplopia after treatment, which was poor compared with other symptoms. No obvious side effects were found in the subsequent follow-up. In conclusion, 32P brachytherapy for Graves' ophthalmopathy was simple and effective, with few side effects, and should be considered as a promising therapy.
Collapse
Affiliation(s)
- Hai-Tao Hao
- Department of Nuclear Medicine, The Red Cross Hospital of Heilongjiang, Harbin, Heilongjiang 150040, P.R. China
| | - Yujun Wang
- Department of Nuclear Medicine, Cancer Hospital of Harbin Medical University, Harbin, Heilongjiang 150081, P.R. China
| | - Xufu Wang
- Department of Nuclear Medicine, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, P.R. China
| | - Sha Luan
- Department of Nuclear Medicine, The 4th Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China
| | - Jianhua Cui
- Department of Nuclear Medicine, The Red Cross Hospital of Heilongjiang, Harbin, Heilongjiang 150040, P.R. China
| | - Yu Chen
- Department of Nuclear Medicine, The Red Cross Hospital of Heilongjiang, Harbin, Heilongjiang 150040, P.R. China
| | - Ya-Li Cui
- Department of Nuclear Medicine, Cancer Hospital of Harbin Medical University, Harbin, Heilongjiang 150081, P.R. China
| |
Collapse
|
9
|
Abstract
Electrophoretic mobility shift assays (EMSA) have proven their usefulness for studying interactions between biological molecules. In the present protocol, a purified protein of interest is mixed with a 5'-end radiolabeled DNA probe. The bound complexes are separated by electrophoretic migration through a polyacrylamide gel and detected with a phosphorimager. The applications of EMSA are diverse, from thermodynamic and kinetic analyses to observation of bending and other conformational changes, stoichiometric inferences, or insights into cooperative protein binding.
Collapse
Affiliation(s)
- Dominic Poulin-Laprade
- Département de Biologie, Faculté des Sciences, Université de Sherbrooke, Sherbrooke, QC, Canada, J1K 2R1
| | - Vincent Burrus
- Département de Biologie, Faculté des Sciences, Université de Sherbrooke, Sherbrooke, QC, Canada, J1K 2R1.
| |
Collapse
|
10
|
Dahmen V, Pomplun E, Kriehuber R. Iodine-125-labeled DNA-Triplex-forming oligonucleotides reveal increased cyto- and genotoxic effectiveness compared to Phosphorus-32. Int J Radiat Biol 2016; 92:679-685. [PMID: 27022855 DOI: 10.3109/09553002.2016.1160157] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
PURPOSE The efficacy of DNA-targeting radionuclide therapies might be strongly enhanced by employing short range particle-emitters. However, the gain of effectiveness is not yet well substantiated. We compared the Auger electron emitter I-125 to the ß--emitter P-32 in terms of biological effectiveness per decay and radiation dose when located in the close proximity to DNA using DNA Triplex-forming oligonucleotides (TFO). The clonogenicity and the induction of DNA double-strand breaks (DSB) were investigated in SCL-II cells after exposure to P-32- or I-125-labeled TFO targeting the glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene and after external homogeneous exposure to gamma-rays as reference radiation. MATERIALS AND METHODS TFO were labeled with P-32 or I-125 using the primer extension method. Cell survival was analyzed by colony-forming assay and DNA damage was assessed by microscopic quantification of protein 53 binding protein 1 (53BP1) foci in SCL-II cells. RESULTS I-125-TFO induced a pronounced decrease of cell survival (D37 at ∼360 accumulated decays per cell, equivalent to 1.22 Gy cell nucleus dose) and a significant increase of 53BP1 foci with increasing decays. The P-32-labeled TFO induced neither a strong decrease of cell survival nor an increase of 53BP1 foci up to ∼4000 accumulated decays per cell, equivalent to ∼1 Gy cell nucleus dose. The RBE for I-125-TFO was in the range of 3-4 for both biological endpoints. CONCLUSIONS I-125-TFO proved to be much more radiotoxic than P-32-TFO per decay and per unit dose although targeting the same sequence in the GAPDH gene. This might be well explained by the high number of low energy Auger electrons emitted by I-125 per decay, leading to a high ionization density in the immediate vicinity of the decay site, probably producing highly complex DNA lesions overcharging DNA repair mechanisms.
Collapse
Affiliation(s)
- Volker Dahmen
- a Radiation Biology Unit, Department of Safety and Radiation Protection , Forschungszentrum Jülich GmbH , Jülich , Germany
| | - Ekkehard Pomplun
- a Radiation Biology Unit, Department of Safety and Radiation Protection , Forschungszentrum Jülich GmbH , Jülich , Germany
| | - Ralf Kriehuber
- a Radiation Biology Unit, Department of Safety and Radiation Protection , Forschungszentrum Jülich GmbH , Jülich , Germany
| |
Collapse
|
11
|
Rosenberg AJ, Liu H, Tu Z. A practical process for the preparation of [(32)P]S1P and binding assay for S1P receptor ligands. Appl Radiat Isot 2015; 102:5-9. [PMID: 25931137 DOI: 10.1016/j.apradiso.2015.04.010] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2015] [Revised: 03/17/2015] [Accepted: 04/15/2015] [Indexed: 10/23/2022]
Abstract
Sphingosine-1-phosphate receptors (S1PRs) are important regulators of vascular permeability, inflammation, angiogenesis and vascular maturation. Identifying a specific S1PR PET radioligand is imperative, but it is hindered by the complexity and variability of current for binding affinity measurement procedures. Herein, we report a streamlined protocol for radiosynthesis of [(32)P]S1P with good radiochemical yield (36-50%) and high radiochemical purity (>99%). We also report a reproducible procedure for determining the binding affinity for compounds targeting S1PRs in vitro.
Collapse
Affiliation(s)
- Adam J Rosenberg
- Department of Radiology, Washington University School of Medicine, 510 South Kingshighway Boulevard, St. Louis, MO 63110, USA
| | - Hui Liu
- Department of Radiology, Washington University School of Medicine, 510 South Kingshighway Boulevard, St. Louis, MO 63110, USA
| | - Zhude Tu
- Department of Radiology, Washington University School of Medicine, 510 South Kingshighway Boulevard, St. Louis, MO 63110, USA.
| |
Collapse
|
12
|
Li Y, Schaffer P, Perrin DM. Dual isotope labeling: conjugation of 32P-oligonucleotides with 18F-aryltrifluoroborate via copper(I) catalyzed cycloaddition. Bioorg Med Chem Lett 2013; 23:6313-6. [PMID: 24144852 DOI: 10.1016/j.bmcl.2013.09.064] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2013] [Revised: 09/19/2013] [Accepted: 09/23/2013] [Indexed: 01/10/2023]
Abstract
A one-pot-two-step labeling of an oligonucleotide with an (18)F-ArBF3(-)(aryltrifluoroborate) radioprosthetic is reported herein. In order to characterize labeling in terms of radiochemistry, phosphorus-32 was also introduced to the 5'-terminus of the oligonucleotide via enzymatic phosphorylation. A pendant azide group was subsequently conjugated to the 5'-phosphate of the oligonucleotide. Copper(I) catalyzed [2+3] cycloaddition was undertaken to conjugate an alkyne-bearing(18)F-ArBF3(-) to the oligonucleotide. Following polyacrylamide gel electrophoresis, this doubly-labeled bioconjugate exhibited decay properties of both the phosphorus-32 and fluorine-18, that were confirmed by autoradiography at selected lengths of time, which in turn provided concrete evidence of successful conjugation. These results are corroborated by HPLC analysis of the labeled material. Taken together this work demonstrates viable use of (18)F-ArBF3(-) prosthetics for labeling oligonucleotides for use in PET imaging.
Collapse
Affiliation(s)
- Ying Li
- Jiangsu Key Laboratory of Atmospheric Environment Monitoring & Pollution Control, College of Environmental Science & Engineering, Nanjing University of Information Science & Technology, 219 Ningliu Road, Nanjing 210044, PR China
| | | | | |
Collapse
|